DEFINITIONS

Celiac disease (CD) is a chronic, immunologically determined form of enteropathy affecting the small intestine in genetically predisposed children and adults. It is precipitated by the ingestion of gluten-containing foods.1,2 It is also referred to as celiac sprue, gluten-sensitive enteropathy, or nontropical sprue.

Gluten can be defined as the rubbery protein mass that remains when wheat dough is washed to remove starch.3 The major protein fractions of gluten, gliadin and glutenin are storage proteins in wheat. They are present in wheat, rye, and barley and give the dough its desired baking properties. Gluten is widely used as an ingredient in food processing.

KEY POINTS

- Gluten and gluten-related proteins present in wheat, rye, and barley are the causative external antigens of CD.
- The prevalence of CD in an adult population varies between roughly 1 in 100 and 1 in 300 in most parts of the world.
- First-degree and (to a lesser extent) second-degree relatives have an increased risk for CD. Its clinical presentation varies widely, and the onset of the disease or symptoms may occur at any time in life.

Many patients with CD have few symptoms or present atypically, whereas a minority of patients have malabsorption (classical CD).

- Patients with active CD have an increased risk of complications, including death, in comparison with the general population. However, this excess rate of major complications seems to return to normal after 3 to 5 years on a strictly gluten-free diet.

Key Diagnostic Findings Include:

- Evidence that the small bowel enteropathy is dependent on gluten shown by positive CD-specific antibodies and/or clinical and/or histologic improvement in response to a gluten-free diet

Serological Tests Can:

- Confirm CD in patients with a demonstrated characteristic enteropathy
- Screen for individuals at risk
- Identify patients in whom biopsy may be warranted.
- Be used to identify gluten consumption during follow-up in diagnosed patients

The presence of autoantibodies directed against transglutaminase-2 suggests that CD has an autoimmune component.4 In adults, CD is diagnosed on average >10 years after the first symptoms appear.5

 Patients with CD should not eat products containing wheat, rye, or barley. Patients usually need to follow a strictly gluten-free diet for the rest of their lives.6 Oats may be consumed, but they are very often contaminated by wheat, and pure oats are often not available. A small subgroup of patients with CD (< 5%) may also be intolerant to pure oats.7

EPIDEMIOLOGY

Introduction

CD is common throughout the world and affects around 1 in 100 to 1 in 300 of the population.8,9 This
prevalence is significantly higher than that recognized 20 years ago. The epidemiology of CD has iceberg characteristics that there are far more undiagnosed cases (below the waterline) than diagnosed cases (above the waterline).

A key study by Fasano et al in 2003 found that the prevalence of CD was as follows:
- At risk, first-degree relatives: 1 in 10
- At risk, second-degree relatives: 1 in 39
- At risk, symptomatic patients: 1 in 56
- Groups not at risk: 1 in 100

Ethnicity

Early epidemiology studies regarded CD as a disease of individuals with white ancestry, mainly located in Europe and North America. However, although there is a lack of worldwide epidemiological information, further studies in other areas of the world have shown a similar prevalence. Some of these studies detected CD among people with Amerindian or African American ancestry. Recent reports have shown that CD is a common disorder in North Africa, the Middle East, India, and Pakistan. Very recent reports from China have shown that both, the CD-predisposing HLA-DQ alleles and the disorder itself are not rare in the provinces of Jiangsu and Zhejiang, at least. The epidemiology of CD has iceberg characteristics that there are far more undiagnosed cases (below the waterline) than diagnosed cases (above the waterline).

At-risk Populations

CD should be considered in the following cases (estimated prevalence are given in brackets, if available):
- First-degree and second-degree relatives of celiac patients (10% and 5%, respectively)
- Unexplained iron-deficiency anemia (3% to 15%)
- Unexplained folic acid, iron, or vitamin B12 deficiency
- Reduced serum albumin
- Unexplained hypertransaminasemia (2% to 9%)
- Osteoporosis and osteomalacia of premature onset (2% to 4%)
- Recurrent abdominal pain or bloating
- Other autoimmune disorders: type 1 diabetes mellitus (2% to 15%), thyroid dysfunction (2% to 7%), Addison disease, and autoimmune hepatitis (3% to 6%)
- Ataxia and idiopathic neuropathy
- Down syndrome and Turner syndrome (6% each)
- Irritable bowel syndrome (3%)

DIAGNOSIS OF CD

Introduction

The considerable increase in the number of patients being diagnosed with CD correlates with the recognition of a remarkably wide variety of clinical manifestations of the disorder, the development of accurate screening tests, and also a true increase in the incidence.

Current Diagnosis

In current practice, the diagnosis of CD hinges on a diagnostic intestinal biopsy and the concomitant presence of a positive CD-specific serology. A second (posttreatment) biopsy is not necessary for most patients if they respond satisfactorily to the specific treatment and should be reserved for patients in whom the first biopsy and serological test are inconclusive (eg, seronegative enteropathy) or for patients on a strict gluten-free diet but fail to respond. A gluten challenge, in which the offending agent is reintroduced while the patient is on a restrictive diet, should be reserved for patients who are receiving treatment but have a doubtful diagnosis.

Diagnostic Tests

Intestinal Biopsy

An intestinal biopsy together with positive serology represents the gold standard in diagnosing CD. In 1992, Marsh reviewed the intensity of mucosal damage observed in treated CD patients who were confronted with increased amounts of gluten. The severity and extent of the histologic damage seem to correlate with the intensity of the clinical symptoms. The proximal damage may be very mild in atypical or silent cases, with little or no abnormality histologically detectable in the intestine. Abnormalities in the gastric and rectal mucosa may be observed in some cases.

The lesion in the duodenum/upper jejunum may be patchy, as a result of which it may be missed if there is insufficient mucosal sampling. Four to 6 biopsy samples must be taken: 3 or 4 from the second part of the duodenum distal to the papilla and at least 1 from the duodenal bulb. A negative histologic diagnosis may justify a second biopsy in selected patients who have positive autoantibodies such as endomysial antibodies (EMA).

Biopsy samples taken from the proximal duodenum above the papilla of Vater may have artifacts (eg, stretching of villi) produced by submucosal Brunner glands, which may be falsely interpreted as flat mucosa.

Under light microscopy, the most characteristic histologic findings in patients who are taking a gluten-containing diet are:
- Blunted or atrophic villi
- Crypt hyperplasia
- Mononuclear cell infiltration in the lamina propria
- Epithelial changes, including structural abnormalities in epithelial cells
- Intraepithelial lymphocyte infiltration

A series of well-designed studies by Marsh made it possible to interpret the wide range of mucosal damage induced by gluten, with the celiac histologic modifications being categorized as ranging from normal mucosa to complete flat villi. The modified Marsh classification is widely used in clinical practice to characterize the histologic damage.

Key factors to be considered for making histologic diagnosis reliable include:
- Number of biopsies procured
- Quality of biopsy samples
- Handling of samples
- Patchiness of mucosal damage
- Different grades of lesion
- Subjective histologic interpretation
Serum Antibodies for Suspicion and Diagnosis of CD

CD-specific serological tests, which have been in use for >20 years now, are important for 2 purposes: to select patients in whom biopsies are appropriate and to confirm the diagnosis in cases in which an enteropathy has been detected. A number of serological markers have been shown repeatedly in many studies to be highly sensitive and specific for untreated CD. On the basis of the target antigens, serological tests for CD can be divided into 2 groups:

- **Autoantibodies:** antiendomysial (EMA) and antitissue transglutaminase (tTG) antibody tests
  - Antibodies targeting the offending agent (gliadin): conventional antigliadin antibodies (nowadays considered obsolete for diagnostic purposes). Antibodies against synthetic deamidated gliadin peptides (DGP) are not recommended.

All of these antibodies are based on immunoglobulin A (IgA) or immunoglobulin G (IgG). Specifically, IgG-based tests are useful for detecting CD in selected IgA-deficient patients.

Choosing the Most Appropriate Serological Test in Different Clinical Scenarios

1. **Serology Pos + Histology Neg**
   - Review or repeat biopsy after 1-2 years
   - Arrange patient follow-up

2. **Serology Pos + Histology Pos**
   - Coeliac Disease confirmed

3. **Serology Neg + Histology Pos**
   - Consider other causes of enteritis
   - If no cause found, treat as Coeliac Disease
   - HLA genotyping

4. **Serology Neg + Histology Neg**
   - Diagnosis excluded

* IgA tissue transglutaminase or endomysial antibody
  - DGP IgG antibodies

** Absence of alleles encoding DQ2, DQ8 make Coeliac Disease unlikely

---

**FIGURE 1.** Diagnosis of celiac disease.
diet. Both IgG DGP seems to be very helpful in IgA-deficient patients and for some EMA-negative and tTG-negative patients.

2. To select patients for duodenal biopsy: to reduce the need for duodenal biopsies, and on the basis of the different accuracy of serological tests, a series of serological algorithms are used to select patients for biopsy in different clinical scenarios:

- From the general population (screening). tTG and DGPs show similar performance and have a high sensitivity. These tests have low positive predictive values in the general (low risk) population (with a prevalence of 1%). A serological algorithm, with serial use of more specific screening assays (eg, EMA) has therefore been widely used to improve the diagnostic accuracy in the general population. A recent study has suggested that the single assay detecting IgA and IgG subtypes of tTG and DGP is the most sensitive test. Simultaneous or serial use of 2 tests (eg, IgA and IgG DGP/tTG plus either IgA (TG or IgA DGP or IgG DGP) provides the highest positive and negative predictive values. A combination of tests therefore improves suspicion of cases.37–44
- Case finding in high-risk populations. Any of the given tests can be used as a single assay, as they all show similar performance as a single test, or in combination. A combination of tests does not improve case finding.

The EMA test requires expert observers, and ELISA tests for detecting tTG antibodies should therefore be recommended in settings with low expertise.35,36

Genetic Testing for Diagnosis

Human leukocyte antigen (HLA) class II haplotypes DQ2 and DQ8 are found in virtually all patients (almost 100% sensitivity) and also in 30% to 40% of the population in Europe, where the great majority will never develop CD. These haplotypes are essential for the recognition of gliadin epitopes by antigen-presenting cells and are therefore a key factor in the development of adaptive immunity. On the basis of its extremely high-negative predictive value, HLA typing can help support exclusion of a diagnosis of CD in equivocal cases in which the patient lacks HLA-DQ2 and DQ8.14,45,46

Role of Endoscopy

Endoscopy is a valuable tool for obtaining duodenal biopsy samples. Endoscopy may show typical duodenal features that are highly predictive of mucosal damage.47–49 Characteristic findings on endoscopy include: scalloped folds, fissures, and a mosaic pattern; flattened folds; and smaller size and/or disappearance of folds with maximum insufflation. Although endoscopic signs of mucosal atrophy have a low sensitivity for diagnosing CD in the general population,50 the procedure is very helpful when these signs are detected during endoscopies that are being conducted for other reasons. In such cases, the endoscopist can follow-up with an intestinal biopsy due to a strong suspicion of mucosal atrophy (Table 1).
decrease very soon after the diet has been instituted. In contrast, complete histologic resolution is not always achieved, or may take years.

**Monitoring**

Compliance is difficult, and patients should therefore be advised of the importance of strict adherence to a gluten-free diet. A multidisciplinary approach can produce more meaningful outcome information. The following is a summary of recommendations for follow-up after diagnosis and tools for monitoring adherence to a gluten-free diet, during the first year after diagnosis (with follow-up appointments every 3 to 6 mo):

- Clinical visits: check symptoms and laboratory tests. CD serology tests (best predictors: quantitative determination of DGP IgA and tTG IgA)
- Visit to an expert nutritionist: assessment of nutritional status and adherence to a gluten-free diet based on an interview, a food diary, and the frequency of consumption (coinciding with the clinical visit)

After the first year and once the patient is stable, visits for consultation can be reduced to 1 per year. Follow-up intestinal biopsy is not required.

**Laboratory Assessment**

Specific serological tests should be less frequent, depending on the degree of compliance and the length of time spent on a gluten-free diet. Recent studies suggest that periodical testing for IgA DGP and/or IgA tTG is the preferred method for monitoring compliance. Although these tests do not identify minor dietary indiscretions, a continued reduction in serum concentrations helps to assess compliance with the diet.

**Nutritionist Consultation**

An expert dietitian should be consulted in order to:

- Assess the patient’s current nutritional status
- Identify macronutrient and/or micronutrient intake and detect deficiencies and/or excesses
- Analyze eating habits and potential factors affecting access to the diet
- Provide information and initiate the gluten-free diet
- Provide dietary education
- Monitor and evaluate dietary compliance and reinforce alimentary counseling

Patients who are unable to adhere to the diet may require support with psychological counseling.

**Persistence of Symptoms**

The persistence of symptoms is almost always caused by continued ingestion of gluten. A common difficulty with the gluten-free diet is cross-contamination and the presence of unsuspected gluten in processed foods and/or medicines (although the latter is rare). Gluten may be a hidden ingredient, so it is prudent for patients to routinely check the ingredient list before purchasing any product; available lists should be checked for allowable food-stuffs. Serology can detect major and continued lapses in dietary adherence.

**Note**

Further details and evidence are available in the full text of this guideline on the World Gastroenterology Organization web site, at: http://www.worldgastroenterology.org/celiac-disease.html.

**REFERENCES**

14. Marsh MN. Gluten major histocompatibility complex, and the persistence of symptoms is almost always caused by continued ingestion of gluten. A common difficulty with the gluten-free diet is cross-contamination and the presence of unsuspected gluten in processed foods and/or medicines (although the latter is rare). Gluten may be a hidden ingredient, so it is prudent for patients to routinely check the ingredient list before purchasing any product; available lists should be checked for allowable food-stuffs. Serology can detect major and continued lapses in dietary adherence. 55

© 2013 Lippincott Williams & Wilkins

www.jcge.com | 125

WGO Global Guidelines on Celiac Disease


